Quantcast

Tissue-selective Estrogen Complex for Menopausal Hormone Therapy.

Research paper by Joann V JV Pinkerton

Indexed on: 01 Jun '18Published on: 01 Jun '18Published in: Clinical obstetrics and gynecology



Abstract

The first approved tissue-selective estrogen complex is a pairing of conjugated estrogen combined with the selective estrogen-receptor modulator, bazedoxifene. Advantages include relief of menopausal symptoms without the increased chance of bleeding or breast tenderness unlike with traditional estrogen-progestin therapy, which is associated with both bleeding and breast tenderness. Tissue-selective estrogen complex effects on relief of vasomotor symptoms, prevention of bone loss, improvement in vaginal symptoms, lack of significant cardiovascular effects beyond the expected 2-fold increase in venous thrombosis, neutral effect on breast, and protective effects on the endometrium are discussed.